[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100475121":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":18,"centralContacts":22,"locations":27,"responsibleParty":43,"collaborators":10,"id":46,"slug":47,"hasResults":48,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":10,"eligibilityCriteria":52,"healthyVolunteers":48,"sex":53,"minAge":54,"maxAge":55,"enrollmentInfo":56,"targetDuration":10,"studyType":59,"phases":10,"briefSummary":60,"conditions":61,"keywords":64,"overallStatus":29,"whyStopped":10,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":76},{"fullName":5,"class":6},"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Experimental ARM",null,"All patients received standard care for postoperative management.",[13],"Other: Standard Management",[15],{"type":6,"name":16,"description":16,"armGroupLabels":17,"otherNames":10},"Standard Management",[9],[19],{"name":20,"affiliation":5,"role":21},"Gong Chang, doctor","PRINCIPAL_INVESTIGATOR",[23],{"name":20,"role":24,"phone":25,"phoneExt":10,"email":26},"CONTACT","02034070499","changgong282@163.com",[28],{"facility":5,"status":29,"city":30,"state":31,"zip":32,"country":33,"countryCode":34,"cosmosGeoPoint":35,"geoPoint":40,"contacts":41},"RECRUITING","Guangzhou","Guangdong","510120","China","CN",{"type":36,"coordinates":37},"Point",[38,39],113.25,23.11667,{"lat":39,"lon":38},[42],{"name":20,"role":24,"phone":25,"phoneExt":10,"email":26},{"type":21,"investigatorFullName":44,"investigatorTitle":45,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Chang Gong","Chief physician","100475121","distribution-of-the-homologous-recombination-related-hrr-genesmutationsand-hrd-in-breast-cancer-100475121",false,"NCT05466786","Distribution of the Homologous Recombination-related (HRR) Genesmutationsand HRD in Breast Cancer","Landscape Ofhomologous Recombination-related (HRR) Genes Mutations and HRD, and Correlation With Survival in HER2-lowbreast Cance","Inclusion Criteria:\n\n1. Female patients aged 18-70 years with pathologically confirmed HER2-low breast cancer (defined as IHC 2+\u002FISH- or IHC 1+ per ASCO\u002FCAP guidelines);\n2. ECOG performance status of 0 or 1;\n3. Treatment-naïve operable primary breast cancer with completed homologous recombination deficiency (HRD) assessment;\n\n5）Absence of distant metastasis; 6）Availability of adequate tumor tissue and blood samples for biomarker analysis.\n\nExclusion Criteria:\n\n1. Recurrent or inoperable locally advanced breast cancer;\n2. Bilateral breast cancer;\n3. History of other malignant tumors within the past 5 years;\n4. Incomplete clinical or pathological data.","FEMALE","18 Years","70 Years",{"count":57,"type":58},255,"ESTIMATED","OBSERVATIONAL","This is a cross-sectional and an observational study, investigator-initiated study in HER2-low breast cancer patients. Approximately 255 subjects with HRD (homologous recombination deficiency) assessment will be enrolled in this study to examine the distribution and features of HRD\u002FHRR (homologous recombination repair).\n\nIn this study, investigators plan to clarify the frequency of HRR\u002FHRD in Chinese patients with HER2-low breast cancer.\n\nIn addition, it is planned to investigate any association between invasive disease-free survival (iDFS)\u002Foverall survival (OS) and HRD\u002FHRR in HER2-low breast cancer patients.",[62,63],"Breast Cancer","HER2-low Breast Cancer",[65,66],"Homologous recombination-related","Homologous recombination deficiency","2025-09-29",{"date":69,"type":70},"2025-10-03","ACTUAL",{"date":72,"type":70},"2022-08-07",{"date":74,"type":58},"2027-05-31",{"name":5,"class":6},1]